Global Human Microbiome Based Drugs and Diagnostics Supply, Demand and Key Producers, 2023-2029

Page: 114

Published Date: 24 Feb 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in better diagnosis of the illness.

This report studies the global Human Microbiome Based Drugs and Diagnostics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Human Microbiome Based Drugs and Diagnostics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Human Microbiome Based Drugs and Diagnostics that contribute to its increasing demand across many markets.

The global Human Microbiome Based Drugs and Diagnostics market size is expected to reach $ 1647 million by 2029, rising at a market growth of 9.9% CAGR during the forecast period (2023-2029).

Rising cases of chronic diseases such as diabetes, disorders at early stage and the ability of the drugs to diagnose them and increased awareness among people to maintain healthy lifestyle is driving the growth of this market.

Highlights and key features of the study
Global Human Microbiome Based Drugs and Diagnostics total market, 2018-2029, (USD Million)
Global Human Microbiome Based Drugs and Diagnostics total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Human Microbiome Based Drugs and Diagnostics total market, key domestic companies and share, (USD Million)
Global Human Microbiome Based Drugs and Diagnostics revenue by player and market share 2018-2023, (USD Million)
Global Human Microbiome Based Drugs and Diagnostics total market by Type, CAGR, 2018-2029, (USD Million)
Global Human Microbiome Based Drugs and Diagnostics total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Human Microbiome Based Drugs and Diagnostics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Second Genome, Enterome Bioscience, Yakult, Dowdupont, Vedanta BioSciences, Metabiomics Corporation, ViThera Pharmaceuticals, MicroBiome Therapeutics and Osel, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Human Microbiome Based Drugs and Diagnostics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Human Microbiome Based Drugs and Diagnostics Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Human Microbiome Based Drugs and Diagnostics Market, Segmentation by Type
    Therapeutics
    Diagnostics

Global Human Microbiome Based Drugs and Diagnostics Market, Segmentation by Application
    Clinical Research Institutes
    Hospital
    Surgical Centers
    Others

Companies Profiled:
    Second Genome
    Enterome Bioscience
    Yakult
    Dowdupont
    Vedanta BioSciences
    Metabiomics Corporation
    ViThera Pharmaceuticals
    MicroBiome Therapeutics
    Osel
    Merck

Key Questions Answered
1. How big is the global Human Microbiome Based Drugs and Diagnostics market?
2. What is the demand of the global Human Microbiome Based Drugs and Diagnostics market?
3. What is the year over year growth of the global Human Microbiome Based Drugs and Diagnostics market?
4. What is the total value of the global Human Microbiome Based Drugs and Diagnostics market?
5. Who are the major players in the global Human Microbiome Based Drugs and Diagnostics market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Human Microbiome Based Drugs and Diagnostics Introduction
    1.2 World Human Microbiome Based Drugs and Diagnostics Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Human Microbiome Based Drugs and Diagnostics Total Market by Region (by Headquarter Location)
        1.3.1 World Human Microbiome Based Drugs and Diagnostics Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Human Microbiome Based Drugs and Diagnostics Market Size (2018-2029)
        1.3.3 China Human Microbiome Based Drugs and Diagnostics Market Size (2018-2029)
        1.3.4 Europe Human Microbiome Based Drugs and Diagnostics Market Size (2018-2029)
        1.3.5 Japan Human Microbiome Based Drugs and Diagnostics Market Size (2018-2029)
        1.3.6 South Korea Human Microbiome Based Drugs and Diagnostics Market Size (2018-2029)
        1.3.7 ASEAN Human Microbiome Based Drugs and Diagnostics Market Size (2018-2029)
        1.3.8 India Human Microbiome Based Drugs and Diagnostics Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Human Microbiome Based Drugs and Diagnostics Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Human Microbiome Based Drugs and Diagnostics Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029)
    2.2 World Human Microbiome Based Drugs and Diagnostics Consumption Value by Region
        2.2.1 World Human Microbiome Based Drugs and Diagnostics Consumption Value by Region (2018-2023)
        2.2.2 World Human Microbiome Based Drugs and Diagnostics Consumption Value Forecast by Region (2024-2029)
    2.3 United States Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029)
    2.4 China Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029)
    2.5 Europe Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029)
    2.6 Japan Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029)
    2.7 South Korea Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029)
    2.8 ASEAN Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029)
    2.9 India Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029)

3 World Human Microbiome Based Drugs and Diagnostics Companies Competitive Analysis
    3.1 World Human Microbiome Based Drugs and Diagnostics Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Human Microbiome Based Drugs and Diagnostics Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Human Microbiome Based Drugs and Diagnostics in 2022
        3.2.3 Global Concentration Ratios (CR8) for Human Microbiome Based Drugs and Diagnostics in 2022
    3.3 Human Microbiome Based Drugs and Diagnostics Company Evaluation Quadrant
    3.4 Human Microbiome Based Drugs and Diagnostics Market: Overall Company Footprint Analysis
        3.4.1 Human Microbiome Based Drugs and Diagnostics Market: Region Footprint
        3.4.2 Human Microbiome Based Drugs and Diagnostics Market: Company Product Type Footprint
        3.4.3 Human Microbiome Based Drugs and Diagnostics Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Human Microbiome Based Drugs and Diagnostics Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Human Microbiome Based Drugs and Diagnostics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Human Microbiome Based Drugs and Diagnostics Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Human Microbiome Based Drugs and Diagnostics Consumption Value Comparison
        4.2.1 United States VS China: Human Microbiome Based Drugs and Diagnostics Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Human Microbiome Based Drugs and Diagnostics Companies and Market Share, 2018-2023
        4.3.1 United States Based Human Microbiome Based Drugs and Diagnostics Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Human Microbiome Based Drugs and Diagnostics Revenue, (2018-2023)
    4.4 China Based Companies Human Microbiome Based Drugs and Diagnostics Revenue and Market Share, 2018-2023
        4.4.1 China Based Human Microbiome Based Drugs and Diagnostics Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Human Microbiome Based Drugs and Diagnostics Revenue, (2018-2023)
    4.5 Rest of World Based Human Microbiome Based Drugs and Diagnostics Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Human Microbiome Based Drugs and Diagnostics Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Human Microbiome Based Drugs and Diagnostics Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Human Microbiome Based Drugs and Diagnostics Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Therapeutics
        5.2.2 Diagnostics
    5.3 Market Segment by Type
        5.3.1 World Human Microbiome Based Drugs and Diagnostics Market Size by Type (2018-2023)
        5.3.2 World Human Microbiome Based Drugs and Diagnostics Market Size by Type (2024-2029)
        5.3.3 World Human Microbiome Based Drugs and Diagnostics Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Human Microbiome Based Drugs and Diagnostics Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Clinical Research Institutes
        6.2.2 Hospital
        6.2.3 Surgical Centers
        6.2.4 Others
        6.2.5 Others
    6.3 Market Segment by Application
        6.3.1 World Human Microbiome Based Drugs and Diagnostics Market Size by Application (2018-2023)
        6.3.2 World Human Microbiome Based Drugs and Diagnostics Market Size by Application (2024-2029)
        6.3.3 World Human Microbiome Based Drugs and Diagnostics Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Second Genome
        7.1.1 Second Genome Details
        7.1.2 Second Genome Major Business
        7.1.3 Second Genome Human Microbiome Based Drugs and Diagnostics Product and Services
        7.1.4 Second Genome Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Second Genome Recent Developments/Updates
        7.1.6 Second Genome Competitive Strengths & Weaknesses
    7.2 Enterome Bioscience
        7.2.1 Enterome Bioscience Details
        7.2.2 Enterome Bioscience Major Business
        7.2.3 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Product and Services
        7.2.4 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Enterome Bioscience Recent Developments/Updates
        7.2.6 Enterome Bioscience Competitive Strengths & Weaknesses
    7.3 Yakult
        7.3.1 Yakult Details
        7.3.2 Yakult Major Business
        7.3.3 Yakult Human Microbiome Based Drugs and Diagnostics Product and Services
        7.3.4 Yakult Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Yakult Recent Developments/Updates
        7.3.6 Yakult Competitive Strengths & Weaknesses
    7.4 Dowdupont
        7.4.1 Dowdupont Details
        7.4.2 Dowdupont Major Business
        7.4.3 Dowdupont Human Microbiome Based Drugs and Diagnostics Product and Services
        7.4.4 Dowdupont Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Dowdupont Recent Developments/Updates
        7.4.6 Dowdupont Competitive Strengths & Weaknesses
    7.5 Vedanta BioSciences
        7.5.1 Vedanta BioSciences Details
        7.5.2 Vedanta BioSciences Major Business
        7.5.3 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Product and Services
        7.5.4 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Vedanta BioSciences Recent Developments/Updates
        7.5.6 Vedanta BioSciences Competitive Strengths & Weaknesses
    7.6 Metabiomics Corporation
        7.6.1 Metabiomics Corporation Details
        7.6.2 Metabiomics Corporation Major Business
        7.6.3 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Product and Services
        7.6.4 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 Metabiomics Corporation Recent Developments/Updates
        7.6.6 Metabiomics Corporation Competitive Strengths & Weaknesses
    7.7 ViThera Pharmaceuticals
        7.7.1 ViThera Pharmaceuticals Details
        7.7.2 ViThera Pharmaceuticals Major Business
        7.7.3 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Product and Services
        7.7.4 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 ViThera Pharmaceuticals Recent Developments/Updates
        7.7.6 ViThera Pharmaceuticals Competitive Strengths & Weaknesses
    7.8 MicroBiome Therapeutics
        7.8.1 MicroBiome Therapeutics Details
        7.8.2 MicroBiome Therapeutics Major Business
        7.8.3 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Product and Services
        7.8.4 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 MicroBiome Therapeutics Recent Developments/Updates
        7.8.6 MicroBiome Therapeutics Competitive Strengths & Weaknesses
    7.9 Osel
        7.9.1 Osel Details
        7.9.2 Osel Major Business
        7.9.3 Osel Human Microbiome Based Drugs and Diagnostics Product and Services
        7.9.4 Osel Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 Osel Recent Developments/Updates
        7.9.6 Osel Competitive Strengths & Weaknesses
    7.10 Merck
        7.10.1 Merck Details
        7.10.2 Merck Major Business
        7.10.3 Merck Human Microbiome Based Drugs and Diagnostics Product and Services
        7.10.4 Merck Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 Merck Recent Developments/Updates
        7.10.6 Merck Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Human Microbiome Based Drugs and Diagnostics Industry Chain
    8.2 Human Microbiome Based Drugs and Diagnostics Upstream Analysis
    8.3 Human Microbiome Based Drugs and Diagnostics Midstream Analysis
    8.4 Human Microbiome Based Drugs and Diagnostics Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Human Microbiome Based Drugs and Diagnostics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Human Microbiome Based Drugs and Diagnostics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Human Microbiome Based Drugs and Diagnostics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Human Microbiome Based Drugs and Diagnostics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Human Microbiome Based Drugs and Diagnostics Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Human Microbiome Based Drugs and Diagnostics Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Human Microbiome Based Drugs and Diagnostics Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Human Microbiome Based Drugs and Diagnostics Players in 2022
    Table 12. World Human Microbiome Based Drugs and Diagnostics Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Human Microbiome Based Drugs and Diagnostics Company Evaluation Quadrant
    Table 14. Head Office of Key Human Microbiome Based Drugs and Diagnostics Player
    Table 15. Human Microbiome Based Drugs and Diagnostics Market: Company Product Type Footprint
    Table 16. Human Microbiome Based Drugs and Diagnostics Market: Company Product Application Footprint
    Table 17. Human Microbiome Based Drugs and Diagnostics Mergers & Acquisitions Activity
    Table 18. United States VS China Human Microbiome Based Drugs and Diagnostics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Human Microbiome Based Drugs and Diagnostics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Human Microbiome Based Drugs and Diagnostics Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Human Microbiome Based Drugs and Diagnostics Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Human Microbiome Based Drugs and Diagnostics Revenue Market Share (2018-2023)
    Table 23. China Based Human Microbiome Based Drugs and Diagnostics Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Human Microbiome Based Drugs and Diagnostics Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Human Microbiome Based Drugs and Diagnostics Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Human Microbiome Based Drugs and Diagnostics Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Human Microbiome Based Drugs and Diagnostics Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Human Microbiome Based Drugs and Diagnostics Revenue Market Share (2018-2023)
    Table 29. World Human Microbiome Based Drugs and Diagnostics Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Human Microbiome Based Drugs and Diagnostics Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Human Microbiome Based Drugs and Diagnostics Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Human Microbiome Based Drugs and Diagnostics Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Human Microbiome Based Drugs and Diagnostics Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Human Microbiome Based Drugs and Diagnostics Market Size by Application (2024-2029) & (USD Million)
    Table 35. Second Genome Basic Information, Area Served and Competitors
    Table 36. Second Genome Major Business
    Table 37. Second Genome Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 38. Second Genome Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Second Genome Recent Developments/Updates
    Table 40. Second Genome Competitive Strengths & Weaknesses
    Table 41. Enterome Bioscience Basic Information, Area Served and Competitors
    Table 42. Enterome Bioscience Major Business
    Table 43. Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 44. Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Enterome Bioscience Recent Developments/Updates
    Table 46. Enterome Bioscience Competitive Strengths & Weaknesses
    Table 47. Yakult Basic Information, Area Served and Competitors
    Table 48. Yakult Major Business
    Table 49. Yakult Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 50. Yakult Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Yakult Recent Developments/Updates
    Table 52. Yakult Competitive Strengths & Weaknesses
    Table 53. Dowdupont Basic Information, Area Served and Competitors
    Table 54. Dowdupont Major Business
    Table 55. Dowdupont Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 56. Dowdupont Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Dowdupont Recent Developments/Updates
    Table 58. Dowdupont Competitive Strengths & Weaknesses
    Table 59. Vedanta BioSciences Basic Information, Area Served and Competitors
    Table 60. Vedanta BioSciences Major Business
    Table 61. Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 62. Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Vedanta BioSciences Recent Developments/Updates
    Table 64. Vedanta BioSciences Competitive Strengths & Weaknesses
    Table 65. Metabiomics Corporation Basic Information, Area Served and Competitors
    Table 66. Metabiomics Corporation Major Business
    Table 67. Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 68. Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. Metabiomics Corporation Recent Developments/Updates
    Table 70. Metabiomics Corporation Competitive Strengths & Weaknesses
    Table 71. ViThera Pharmaceuticals Basic Information, Area Served and Competitors
    Table 72. ViThera Pharmaceuticals Major Business
    Table 73. ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 74. ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. ViThera Pharmaceuticals Recent Developments/Updates
    Table 76. ViThera Pharmaceuticals Competitive Strengths & Weaknesses
    Table 77. MicroBiome Therapeutics Basic Information, Area Served and Competitors
    Table 78. MicroBiome Therapeutics Major Business
    Table 79. MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 80. MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. MicroBiome Therapeutics Recent Developments/Updates
    Table 82. MicroBiome Therapeutics Competitive Strengths & Weaknesses
    Table 83. Osel Basic Information, Area Served and Competitors
    Table 84. Osel Major Business
    Table 85. Osel Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 86. Osel Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. Osel Recent Developments/Updates
    Table 88. Merck Basic Information, Area Served and Competitors
    Table 89. Merck Major Business
    Table 90. Merck Human Microbiome Based Drugs and Diagnostics Product and Services
    Table 91. Merck Human Microbiome Based Drugs and Diagnostics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 92. Global Key Players of Human Microbiome Based Drugs and Diagnostics Upstream (Raw Materials)
    Table 93. Human Microbiome Based Drugs and Diagnostics Typical Customers
List of Figure
    Figure 1. Human Microbiome Based Drugs and Diagnostics Picture
    Figure 2. World Human Microbiome Based Drugs and Diagnostics Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Human Microbiome Based Drugs and Diagnostics Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Human Microbiome Based Drugs and Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Human Microbiome Based Drugs and Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Human Microbiome Based Drugs and Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Human Microbiome Based Drugs and Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Human Microbiome Based Drugs and Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Human Microbiome Based Drugs and Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Human Microbiome Based Drugs and Diagnostics Revenue (2018-2029) & (USD Million)
    Figure 13. Human Microbiome Based Drugs and Diagnostics Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Human Microbiome Based Drugs and Diagnostics Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Human Microbiome Based Drugs and Diagnostics by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Human Microbiome Based Drugs and Diagnostics Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Human Microbiome Based Drugs and Diagnostics Markets in 2022
    Figure 27. United States VS China: Human Microbiome Based Drugs and Diagnostics Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Human Microbiome Based Drugs and Diagnostics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Human Microbiome Based Drugs and Diagnostics Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Human Microbiome Based Drugs and Diagnostics Market Size Market Share by Type in 2022
    Figure 31. Therapeutics
    Figure 32. Diagnostics
    Figure 33. World Human Microbiome Based Drugs and Diagnostics Market Size Market Share by Type (2018-2029)
    Figure 34. World Human Microbiome Based Drugs and Diagnostics Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 35. World Human Microbiome Based Drugs and Diagnostics Market Size Market Share by Application in 2022
    Figure 36. Clinical Research Institutes
    Figure 37. Hospital
    Figure 38. Surgical Centers
    Figure 39. Others
    Figure 40. Human Microbiome Based Drugs and Diagnostics Industrial Chain
    Figure 41. Methodology
    Figure 42. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Human Microbiome Based Drugs and Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Human Microbiome Based Drugs and Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 02 Jan 2023

date Medical Care

The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in better diagnosis of the illness.

Global Human Microbiome Based Drugs and Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Human Microbiome Based Drugs and Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 30 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Human Microbiome Based Drugs and Diagnostics market size was valued at USD 851.9 million in 2023 and is forecast to a readjusted size of USD 1647 million by 2030 with a CAGR of 9.9% during review period.

Product Tags

Human Microbiome Based Drugs and Diagnostics

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>